

I-Mab BioPharma (IMAB US)

Promising Phase 1 data of anti-CD47 antibody at the 2020 SITC Annual Meeting

- Phase 1 results demonstrate differentiated safety and PK profile and efficacy signal of lempzoparlimab (TJC4).** Lemzoparlimab is a highly differentiated CD47 antibody designed to minimize inherent binding to normal red blood cells while preserving its strong anti-tumor activity. I-Mab released in a poster at the 2020 SITC Annual Meeting, demonstrating the initial results of its US phase 1 clinical trial (NCT03934814) evaluating lempzoparlimab for the treatment of relapsed or refractory solid tumors and lymphoma. Lemzoparlimab is well tolerated as a single agent at a dose range of up to 30 mg/kg without introducing any priming dosing strategy. In all DLT-evaluable patients, no dose-limiting toxicities or severe hematologic adverse events were observed. Lemzoparlimab PK appears to be linear at mid to high dose levels following a single dose with no significant "sink effect". One confirmed partial response (PR) was observed in a melanoma patient in the 30 mg/kg monotherapy cohort (N=3), who had failed prior treatments with checkpoint inhibitors.
- Multiple ongoing trials in the US and China.** The above mentioned US phase I study (NCT03934814) includes in two parts. The first part is comprised of a single agent dose escalation followed by two separate combination regimens in an escalating dose range (Part 1b with pembrolizumab; Part 1c with rituximab). The second part is a dose expansion study in the combination therapies. The data released at SITC 2020 is the single agent dose escalation in first part. Recruitment of patients for the dose escalation study of lempzoparlimab in combination with pembrolizumab or rituximab is ongoing. In China, I-Mab is conducting a phase I trial of lempzoparlimab for hematologic tumors which has finished 20mg/kg in dose escalation and was expected to be finished by 1Q21.
- Significant synergies from the global strategic partnership with AbbVie.** I-Mab reached a broad, global collaboration agreement with AbbVie for the development and commercialization of lempzoparlimab. I-Mab retains all rights to develop and to commercialize lempzoparlimab in mainland China, Macau and Hong Kong. Going forward, I-Mab will work closely with AbbVie to facilitate clinical development of lempzoparlimab both globally and in China. We expect the two partners to expand the collaboration to additional transformative therapies. We see potential significant clinical synergies between I-Mab's lempzoparlimab and AbbVie's Venclexta (Venetoclax, a Bcl-2 inhibitor) in treating AML and MDS.
- Maintain BUY.** We maintain our DCF-based TP unchanged at US\$52.57 (WACC: 10.6%, terminal growth rate: 3.0%).

Earnings Summary

(YE 31 Dec)	FY18A	FY19A	FY20E	FY21E	FY22E
Revenue (RMB mn)	54	30	1,400	1,533	806
YoY growth (%)	365	(44)	4,567	N/A	(47)
Net loss (RMB mn)	(403)	(1,452)	204	(674)	(1,157)
EPS (RMB per ADS)	N/A	N/A	2.89	(9.56)	(16.41)
R&D expenses (RMB mn)	(426)	(840)	(900)	(1,000)	(1,050)
Capex (RMB mn)	(14)	(12)	(100)	(100)	(100)

Source: Company data, CMBIS estimates

BUY (Maintain)

Target Price	US\$52.57
(Previous TP)	US\$52.57)
Up/Downside	+59.59%
Current Price	US\$32.94

China Healthcare Sector

Jill Wu, CFA

(852) 3900 0842
jillwu@cmbi.com.hk

Sam Hu, PhD

(852) 3900 0882
samhu@cmbi.com.hk

Mkt. Cap. (US\$ mn)	2,322
Avg. 3mths t/o (US\$ mn)	9.13
52W High/Low (US\$)	47.46/9.30
Total Issued Shares (mn)	70

Source: Bloomberg

Shareholding Structure

Founders	3%
Pre-IPO investors	68%
Other public shareholders	29%


Source: Bloomberg

Share performance

	Absolute	Relative
1-mth	-16.8%	-17.8%
3-mth	9.5%	2.9%
6-mth	101.5%	56.9%

Source: Bloomberg

12-mth price performance



Source: Bloomberg

Auditor: PWC

Web-site: www.i-mabbiopharma.com

Related report:

Global strategic partnership with AbbVie – 7 Sep 2020
Innovation for biologics – 26 Aug 2020

Competition landscape in CD47 therapies

Worldwide, more than 15 drug candidates targeting CD47 are under clinical tests, including mAbs, fusion proteins and BsAbs. The most leading asset is Hu5F9-G4 (Magrolimab) developed by Forty Seven, a subsidiary of Gilead. Gilead is initiating a registrational Phase 3 trial to test magrolimab in MDS patients. Other anti-CD47 biological candidates are all in early phase of development. In China, six anti-CD47 biological candidates are in early clinical phase while another three candidates may start clinical studies soon.

However, almost all clinical trials with CD47 antibodies so far have shown significant hematologic adverse effects, likely due to inherent RBC-binding properties of generic CD47 antibodies. So far, the development of some CD47 targeting drug candidates were terminated, such as SRF231 by Surface Oncology, CC-90002 by Celgene.

Figure 1: Competition landscape in CD47 biological therapies

Product	Molecule	Company	US status	China status
Hu5F9-G4 (Magrolimab)	CD47 mAb	Forty Seven / Gilead	Phase 3 in 1L higher-risk MDS (+ Azacitidine); Phase 1b in AML (+ Azacitidine); Phase 1/2 in DLBCL (+ Rituximab); Phase 1/2 in Colorectal cancer (+ Cetuximab); Phase 1 in Ovarian cancer (+ Avelumab)	N/A
TTI-621	CD47 WT SIRPα fusion protein	Trillium Therapeutics	Phase 1	N/A
TTI-662	CD47 WT SIRPα fusion protein	Trillium Therapeutics	Phase 1	N/A
ALX148	CD47 high affinity SIRPα fusion protein	ALX Oncology	Phase 1/2 in higher risk MDS (+ Azacitidine)	N/A
AO-176	CD47 mAb	Arch Oncology	Phase 1/2 in r/r MM	N/A
TG-1801 (NI-1701)	CD47/CD19 BsAb	TG Therapeutics / Novimmune	Phase 1	N/A
IBI188	CD47 mAb	Innovent	Phase 1	Phase 1b/3 in 1L MDS; Phase 1b/2 in r/r AML
SHR1603	CD47 mAb	Hengrui Medicine	N/A	Phase 1
IMM01	CD47 mAb-Trap fusion protein	Immune Onco	N/A	Phase 1
TJC4 (TJ011133)	CD47 mAb	I-Mab	Phase 1	Phase 1/2a in r/r AML
HX009	PD-1/CD47 BsAb	HanX Biopharma	N/A	Phase 1
IMM0306	CD47/CD20 BsAb	Immune Onco	N/A	Phase 1
IBI322	CD47/PD-L1 BsAb	Innovent	N/A	IND approval
ZL-1201	CD47 mAb	ZaiLab	Phase 1	IND approval
AK117	CD47 mAb	Akeso Biopharma	N/A	IND filing

Source: Insight, Clinicaltrials.gov, CMBIS

Figure 2: Summary of clinical data of leading CD47-SIRPα targeting therapies

Drug	Magrolimab (Hu-5FG)	Magrolimab (Hu-5FG)	Magrolimab (Hu-5FG)	Magrolimab (Hu-5FG)	Magrolimab (Hu-5FG)	TTI-621	TTI-621	TTI-621	TTI-621	ALX-148	ALX-148	ALX-148
Target	CD47	CD47	CD47	CD47	CD47	SIRPα	SIRPα	SIRPα	SIRPα	SIRPα	SIRPα	SIRPα
Company	Forty Seven	Forty Seven	Forty Seven	Forty Seven	Forty Seven	Trillium Therapeutics	Trillium Therapeutics	Trillium Therapeutics	Trillium Therapeutics	ALX Oncology	ALX Oncology	ALX Oncology
Trial ID	NCT03248479	NCT03248479	NCT02953509	NCT02953509	NCT03248479	NCT02663518	NCT02663518	NCT02663518	NCT02663518	NCT03013218	NCT03013218	NCT03013218
Phase	1b	1b	1b/2	1b/2	1b	1	1	1	1	1b	1b	1b
Treatment	+Azacitidine	+Azacitidine	+Rituximab	+Rituximab	mono	mono	mono	mono	+Rituximab	+Rituximab	+Keytruda	+Herceptin
Indication	1L MDS	1L AML	3L+ DLBCL	2L+ FL or MZL	r/r-AML/MDS	r/r-CTCL	r/r-PTCL	r/r-DLBCL	r/r-DLBCL	3L+ ALL	2L SCCHN	r/r-Her2+Gastric/GE J
No. of patients	33	25	59	38 (35+3)	10	42	22	7	25	33	20	19
ORR (%)	91%	64% (75% (9/12) for TP53m)	36%	61%	10%	19%	18%	29%	24%	45% (15/33)	20% (4/20)	21.1% (4/19)
CR	42%	40% (42% (5/12) for TP53m)	15%	24%	0%	2%	9%	14%	4%			
CRi		16% (33% (4/12) for TP53m)										
PR	3%	4%	20%	37%	10%	17%	9%	14%	20%			
marrow CR / MLFS	24% (4/8 with HI)	4%										
Heamatologic Improvement (HI)	21%											
SD	9%	32%	12%	24%	70%							
PD	0%	4%	17%	16%	10%							
Anemia		38%		29%	20%			13% (≥G3=8%)		6.1% (≥G3=3.0%)	9.6% (≥G3=1.9%)	6.7% (≥G3=0%)
Fatigue		21%						15% (≥G3=0%)		9.1% (≥G3=0%)	11.5% (≥G3=0%)	30.0% (≥G3=0%)
Neutropenia		19%		19%	0%			8% (≥G3=7%)		6.1% (≥G3=6.1%)	3.8% (≥G3=1.9%)	6.7% (≥G3=6.7%)
Thrombocytopenia		18%		14%	0%			28% (≥G3=21%)				
Infusion reaction		16%						41% (≥G3=2%)		0%	7.7% (≥G3=0%)	0%

Source: ASH 2019, EHA 2019, ASCO2019, ALXOncology prospectus, company data, CMBIS

DCF-based TP of US\$52.57

Given the recent progresses such as the release of differentiated safety and PK profile and preliminary efficacy of TJC4 (lemzoparlimab), global partnership with AbbVie on lemzoparlimab and the completion of private placement, we derive our TP of US\$52.57 based on 15-year risk-adjusted DCF model (WACC: 10.6%, terminal growth rate: 3.0%).

Figure 3: Risk-adjusted DCF valuation

DCF Valuation (in Rmb mn)	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E	2035E
EBIT	(674)	(1,157)	(1,386)	2,641	1,202	1,605	2,445	2,893	3,201	3,588	3,966	4,357	4,771	5,145	5,609
Tax rate	0%	0%	0%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%
EBIT*(1-tax rate)	(674)	(1,157)	(1,386)	2,245	1,022	1,364	2,078	2,459	2,721	3,050	3,371	3,703	4,056	4,374	4,768
+ D&A	35	46	55	62	69	74	78	82	85	87	89	91	93	94	95
- Change in working capital	(579)	205	72	(352)	(307)	(302)	(204)	(165)	(59)	(106)	(107)	(101)	(102)	(103)	(105)
- Capex	(100)	(100)	(100)	(100)	(100)	(100)	(100)	(100)	(100)	(100)	(100)	(100)	(100)	(100)	(100)
FCFF	(1,318)	(1,006)	(1,360)	1,855	683	1,036	1,852	2,276	2,646	2,932	3,254	3,593	3,946	4,264	4,658
Terminal value															63,145
FCF + Terminal value	(1,318)	(1,006)	(1,360)	1,855	683	1,036	1,852	2,276	2,646	2,932	3,254	3,593	3,946	4,264	67,803
Present value of enterprise (RMB mn)	22,489														
Net debt (RMB mn)	(3,453)														
Equity value (RMB mn)	25,942														
Equity value (US\$ mn)	3,706														
No. of ADS	70,495,716														
DCF per share (US\$)	52.57														
Terminal growth rate	3.0%														
WACC	10.60%														
Cost of Equity	13.5%														
Cost of Debt	4.5%														
Equity Beta	1.0														
Risk Free Rate	3.0%														
Market Risk Premium	10.5%														
Target Debt to Asset ratio	30.0%														
Effective Corporate Tax Rate	15.0%														

Source: CMBIS estimates

Figure 4: Sensitivity analysis (US\$)

		WACC				
		9.60%	10.10%	10.60%	11.10%	11.60%
Terminal growth rate	2.0%	58.47	53.43	49.04	45.19	41.80
	2.5%	60.90	55.43	50.70	46.58	42.96
	3.0%	63.69	57.70	52.57	48.13	44.26
	3.5%	66.94	60.32	54.71	49.89	45.72
	4.0%	70.78	63.38	57.17	51.89	47.37

Source: Company data, CMBIS estimates

Financial Statements

Income statement						Cash flow summary					
YE 31 Dec (RMB mn)	FY18A	FY19A	FY20E	FY21E	FY22E	YE 31 Dec (RMB mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Revenue	54	30	1,400	1,533	806	Profit before tax	(401)	(1,452)	240	(674)	(1,157)
Cost of sales	0	0	0	(307)	(153)	D&A, etc.	7	16	22	35	46
Gross profit	54	30	1,400	1,226	653	Change in working capital	148	185	(74)	(579)	205
Administrative expenses	(66)	(655)	(300)	(345)	(397)	Tax paid	(2)	0	(36)	0	0
R&D expenses	(426)	(840)	(900)	(1,000)	(1,050)	Others	(33)	384	0	0	0
Selling expenses	0	0	0	(613)	(403)	Net cash from operating activities	(281)	(868)	152	(1,218)	(906)
Fair value change of warrants	61	6	0	0	0	Capex	(14)	(12)	(100)	(100)	(100)
Operating profit	(377)	(1,459)	200	(732)	(1,197)	Net proceeds from disposal of short-term investments	0	(32)	0	0	0
Finance costs, net	(7)	28	40	58	40	Other investing activities	24	257	0	0	0
Other income (expenses), net	(17)	(20)	0	0	0	Net cash from investing activities	10	212	(100)	(100)	(100)
Pre-tax profit	(401)	(1,452)	240	(674)	(1,157)	Net proceeds from shares issued	1,307	184	3,652	0	0
Income tax	(2)	0	(36)	0	0	Net bank borrowing	(19)	(30)	0	0	0
Minority interests	0	0	0	0	0	Proceeds from issuance of convertible promissory notes	60	0	0	0	0
Net profit (Net loss)	(403)	(1,452)	204	(674)	(1,157)	Other financing activities	132	(1)	0	0	0
						Net cash from financing activities	1,480	153	3,652	0	0
						FX changes	60	15	0	0	0
						Net change in cash	1,208	(503)	3,704	(1,318)	(1,006)
						Cash at the beginning of the year	413	1,681	1,193	4,897	3,579
						Cash at the end of the year	1,681	1,193	4,897	3,579	2,573

Balance sheet						Key ratios					
YE 31 Dec (RMB mn)	FY18A	FY19A	FY20E	FY21E	FY22E	YE 31 Dec	FY18A	FY19A	FY20E	FY21E	FY22E
Non-current assets	339	376	455	520	574	Profit & loss ratios (%)					
PP&E	28	30	108	174	228	Gross margin	100	100	100	80	81
Operating lease right of use assets	0	16	16	16	16	EBITDA margin	N/A	N/A	N/A	(45.47)	(142.83)
Intangible assets	149	149	149	149	149	Net margin	N/A	N/A	N/A	(43.98)	(143.51)
Goodwill	163	163	163	163	163	Effective tax rate (%)	N/A	N/A	N/A	N/A	N/A
Other non-current assets	0	18	18	18	18	Balance sheet ratios					
Current assets	2,037	1,361	5,065	4,226	2,990	Current ratio (x)	6	2	10	10	8
Inventories	0	0	0	101	50	Trade receivables turnover	N/A	N/A	N/A	90	90
Trade and bills receivables	0	0	0	378	199	Trade payables turnover	N/A	N/A	N/A	180	180
Prepayments, other receivables	89	136	136	136	136	Total debt to asset ratio (%)	17	38	11	10	13
Other financial assets	256	0	0	0	0	Returns (%)					
Cash and bank balances	1,588	1,137	4,841	3,523	2,517	ROE	(21)	(136)	4	(16)	(37)
Current liabilities	346	588	515	415	390	ROA	(17)	(84)	4	(14)	(32)
Short-term borrowings	80	50	50	50	50	Per share data					
Advance from customers	14	0	0	0	0	EPS (RMB)	N/A	N/A	2.9	(9.6)	(16.4)
Other payables and accruals	68	274	200	100	76	DPS (RMB)	0.0	0.0	0.0	0.0	0.0
Operating lease liabilities, current	0	7	7	7	7	BVPS (RMB)	N/A	N/A	69.9	60.3	43.9
Other current liabilities	184	258	258	258	258						
Non-current liabilities	70	80	80	80	80						
Convertible promissory notes	67	68	68	68	68						
Onshore convertible loans	0	7	7	7	7						
Deferred subsidy income	3	4	4	4	4						
Total net assets	1,960	1,069	4,925	4,251	3,094						
Minority interest	0	0	0	0	0						
Shareholders' equity	1,960	1,069	4,925	4,251	3,094						

Source: Company data, CMBIS estimates

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIS Ratings

BUY	: Stock with potential return of over 15% over next 12 months
HOLD	: Stock with potential return of +15% to -10% over next 12 months
SELL	: Stock with potential loss of over 10% over next 12 months
NOT RATED	: Stock is not rated by CMBIS
OUTPERFORM	: Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM	: Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Securities Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Securities Limited ("CMBIS") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,") of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

For recipients of this document in the United States

CMBIS is not a registered broker-dealer in the United States. As a result, CMBIS is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.